Mitchell Warren
As seen in:
HuffPost,
Wiley Online Library,
Seeking Alpha,
The Hill,
News24,
The Street,
STAT,
The Lancet,
AllAfrica,
Daily Maverick
and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Mitchell Warren
The Future of the HIV Response: Sustaining Progress in an era of Political Uncertainty and Scientific Opportunity
1 Introduction More than forty years after the identification of HIV, the global response stands at a moment of both extraordinary promise and profound uncertainty. Scientific advances have transformed HIV from a fatal diagnosis into a manageable chronic condition and have introduced highly effective prevention strategies capable of dramatically reducing new infections. Yet, the infrastructure required to translate these advances into population-level impact is increasingly fragile.
HIV prevention jab is finally here, now comes the hard part
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies.
HIV prevention jab is finally here, now comes the hard part
South Africa is about to begin one of the most important HIV prevention drives in decades. Earlier this month, Health Minister, Aaron Motsoaledi, announced the country will launch its roll-out of the once-every-six month HIV prevention injection, lenacapavir (LEN), on June 5 in Mpumalanga. Roll-out will be across South Africa, initially at 360 government clinics. The moment matters. LEN, an injection taken only twice a year, is one of the biggest advances in HIV prevention.
The HIV prevention jab scientists hoped for is finally here. Now comes the hard part
On June 5, South Africa will begin one of its most important HIV prevention drives in decades. The country will start to roll out an HIV prevention injection that has to be taken only twice a year. But new medicines alone do not stop epidemics. Health systems, political choices and funding determine whether the medication reaches the people who need it.
The HIV prevention jab scientists hoped for is finally here. Now comes the hard part
On June 5, South Africa will begin one of its most important HIV prevention drives in decades. The country will start to roll out an HIV prevention injection that has to be taken only twice a year. But new medicines alone do not stop epidemics. Health systems, political choices and funding determine whether the medication reaches the people who need it.
U.S. retreat from WHO harms global health and the HIV response
On January 22, 2026, the United States took another giant step away from its role as a global leader, betraying American citizens and the rest of the world by withdrawing from the World Health Organization (WHO). Since 1948, WHO has been the United Nations agency tasked with directing global public health standards and guidelines and responding to health emergencies. The U.S. was a founding member of WHO and for over 75 years has both benefited from membership and contributed to its impact.
Future directions: ending HIV in Africa-a call to action for sustainable and nationally led prevention
This is the second in a Series of 6 papers about sustainable HIV prevention in Africa (papers 1, 4, and 5 appear in The Lancet HIV).
Opinion: The US legacy in HIV is unraveling
Right now, the U.S. global AIDS response could best be described as rearranging deck chairs while the ship drifts entirely off course. We are not witnessing bold reform, but an intentional unraveling of America’s legacy in global health. And it’s happening without the congressional engagement that has, historically, yielded such remarkable success. Reimagining and realigning global health programs is not inherently bad.
Bending the curve: What a decade-long roll-out of the anti-HIV pill can teach the world
By September, over five million people worldwide had started using PrEP (short for pre-exposure prophylaxis). This means taking medicine before sex to prevent getting infected with HIV. At just over a million users, South Africa makes up about a fifth of the total.
What decade-long roll-out of the anti-HIV pill can teach the world
BHEKISISA OP-ED What can the roll-out of a two-monthly HIV prevention injection learn from how the daily anti-HIV pill was introduced? Create demand, make the jab easy to get hold of and ensure it’s not stigmatised, write Wawira Nyagah and Mitchell Warren. By September, more than five million people worldwide had started using PrEP (pre-exposure prophylaxis) – taking medicine before sex to prevent becoming infected with HIV.
Bending the curve: What a decade-long roll-out of the anti-HIV pill can teach the world
By September, over five million people worldwide had started to use HIV prevention medication — about a fifth live in South Africa. The most commonly used prevention medicine has been a daily pill. But its uptake has been much slower than expected. The pill’s roll-out has taught us that people don’t use medicine simply because it’s available — we need to create demand, make prevention medicine easy to get hold of and ensure it’s not stigmatised.
Vaccine equity: The rollout that needs a booster shot
We are over a year into one of the most challenging rollouts of a global health technology product — the COVID-19 vaccines. With almost half the world fully vaccinated against the pandemic, we can look at the glass as either half full or half empty — it depends on where you are and who you are. The lowest vaccination rates can be found in low-income or low-middle income countries, and among the most marginalized populations within nearly every country.
MAVERICK CITIZEN: OP-ED: UN shift on HIV prevention raises hope we can end Aids by 2030 – now we need to turn words into action
People around the world unite to show support for people living with and affected by HIV and to remember those who lost their lives to Aids. (Photo: nytimes.com/Wikipedia) The latest UN Declaration on Aids does not speak more forcefully on the need to protect the human rights of key populations at risk for HIV, but there are significant shifts, including an unprecedented commitment to HIV combination prevention. Sheila Tlou and Mitchell Warren are co-chairs of the Global HIV Prevention Coalition.
Opinion: US leadership matters in fighting AIDS
A pharmacy manager with HIV rapid test kits at a health center in Ethiopia. The center is in an area at high risk for HIV transmission, according to the U.S. President’s Emergency Plan for AIDS Relief. Photo by: USAID Global Health Supply Chain via Twitter U.S. President Joe Biden has repeatedly praised the United States’ leadership in the global effort to end HIV/AIDS.
South Africa: Finding an HIV Vaccine - Five Lessons From the Response to Covid-19
The Covid-19 pandemic has revealed that vaccine development and testing timelines can be shrunk from decades to months. Here's a look at what we can learn from the search for a Covid-19 vaccine. Fatima Hassan is the founder and director of the Health Justice Initiative. Mitchell Warren is the executive director of the US-based advocacy organisation, AVAC.
Finding an HIV vaccine: Five lessons from the search for a Covid-19 jab
The Covid-19 pandemic saw vaccine development shrink from decades to months But this scientific progress also highlighted the cost of inequity when interventions are not available to poorer countries We look at five lessons from the successes and mistakes in the search for a Covid vaccine and how these could help other pandemics The way in which the world has responded to Covid, has fundamentally changed ideas of what’s possible in vaccine development - but, regrettably, access to that...
Opinion: Why exciting results from vaccine research are just the beginning of efforts to end COVID-19
Laboratory services are being developed for accurate disease detection, confirmation, treatment, and monitoring in sub-Saharan Africa. Photo by: CDC Global / CC BY The news last week and again this week that at least two highly effective vaccines may be on the horizon is a welcome respite from the devastating impact of COVID-19 on global health. In under a year, SARS-CoV-2 has already caused more than 56 million infections and 1.3 million deaths.
Science, Not Politics, Must Lead to COVID Vaccine Approvals
Opinions Political pressure to speed the introduction of COVID vaccines threatens scientifically proven systems to protect public safety and research integrity. September 30, 2020 • By Uché Blackstock and Mitchell Warren COVID-19 has devastated communities and health systems around the world — but it has also created an historic global effort leading to the unprecedented development of more than 165 potential vaccines against COVID-19.
Opinion: To accelerate search for COVID-19 vaccine, look to HIV and act globally
Two vials used by the research and development arm of the International AIDS Vaccine Initiative, which designs and develops HIV vaccine candidates. Photo by: Charlotte Raymond / International AIDS Vaccine Initiative / CC BY-NC-ND In just six months, the virus that causes COVID-19 has spread around the world, infected over 5 million people, and exacted devastating public health and economic tolls that are only just beginning.
How COVID-19 must transform US global health strategy
While the COVID-19 pandemic is raging in the U.S., Africa faces the prospect of imminent catastrophe, where at least 300,000 Africans could die from the disease and 29 million people may be pushed into extreme poverty. Viruses do not respect borders, and we know that America will not be safe if COVID-19 is out of control on other continents.
Opinion: We won't meet the 2020 AIDS targets. Now what?
A patient preps medications in his bedroom at a HIV/AIDS center in Yangon, Myanmar. Photo by: REUTERS / Ann Wang As we approach 2020 — a pivotal year on many levels — we have more options and a clearer picture than ever of what must be done to end the HIV epidemic globally. But in 2019 we learned some hard lessons about how far we still have to go: a range of prevention trials brought new data on both the potential and the limitations of biomedical strategies in the global HIV response.
HIV Testing: A Portal for Treatment and Prevention
For years, HIV testing has been the cornerstone of plans to end the HIV/AIDS epidemic. Widespread testing programs have helped connect millions of people to HIV treatment and care and have been the first step in saving lives. However, an estimated 14 million more people who are living with HIV still haven't been tested and remain unaware of their status and unconnected to the treatment and care they need, according to the World Health Organization.
Alibaba (BABA) Shares Look Poised To Hit New All Time High
Alibaba Group (NASDAQ:BABA) had a successful start after going public in late 2014, pricing at $68 per share and quickly soaring to $120 by November. However, the IPO honeymoon phase quickly turned sour at the start of 2015 as shares fell below $90 in January. And close to the 1-year IPO anniversary, shares of Alibaba stock (BABA) were trading sub-$60 per share. Since then the stock has been steadily trending higher.
Correction: Voluntary Medical Male Circumcision for HIV Prevention: New Mathematical Models for Strategic Demand Creation Prioritizing Subpopulations by Age and Geography
There is an error in the Funding statement. The number for the Cooperative Agreement Project SOAR (Supporting Operational AIDS Research) is incorrect. The correct number is OAA-A-14-00060. Citation: Hankins C, Warren M, Njeuhmeli E (2016) Correction: Voluntary Medical Male Circumcision for HIV Prevention: New Mathematical Models for Strategic Demand Creation Prioritizing Subpopulations by Age and Geography. PLoS ONE 11(12): e0169499. doi:10.1371/journal.pone.0169499 Copyright: © 2016 Hankins et al.
Will the HIV prevention pill slow down HIV infections?
PrEP is not a magic bullet. But we won’t end the HIV epidemic without it. Almost exactly six years ago, researchers published findings from the first study to show that a pill a day could drastically reduce the risk of HIV infection. This was tantalising evidence that “pre-exposure prophylaxis”, or PrEP, could be one more way to protect people against the virus. In the subsequent two years, multiple trials confirmed the result among different populations.
In Childhood Vaccine Controversy, an Indirect Lesson for HIV/AIDS Advocates
From all the recent attention to parents' rejection (and some politicians' naiveté) of vaccines and a possible resurgence of measles in the United States, one welcome theme has emerged: Such a controversy could never occur if vaccines weren't so powerfully effective in the first place.
2 Oil Refiners Ready To Rise In 2016
2015 was a year dominated by crashing commodity headlines (especially oil prices) and chatter of when the Federal Reserve was finally going to hike rates for the first time since 2006. The 10-15% drop in integrated energy companies like Chevron and BP may seem like a common occurrence or even 25-50% hair cuts in the smaller, more leveraged producers, but there was a bright spot in the industry for investors: select oil refiners stocks.
Is It Time To Fade The Rally In US Steel Corp (X)?
Shares of United States Steel Corp. (X) have collapsed 81% from the 2014 highs, but is it still too early to call for a bottom in the once great steel producer? China’s mass production rate of steel has led to “dumping” in the United States and other areas of the world, which essentially means those foreign competitors are selling below or at production costs. Tack on a stronger U.S. Dollar and you have continued downward pressure on the likes of US Steel, Nucor (NUE), AK Steel (AKS), and more.
Unusual Options Activity: TGT, GPS, FAST, URBN, And More
It’s time to review several stocks that had unusual options activity over the last week. Although traders can never be sure why these trades take place (and who’s making them), I believe it’s important to be aware of notable options activity as an indicator for directional bias. Here’s a weekly recap of 10 stocks that had unusual options activity and what, if any, significance these trades may have. Urban Outfitters (URBN) – 6,000 Aug $32 puts were purchased for $1.07-$1.30.
Crude Oil Inventories Pressuring Nabors Stock (NBR)
The Uptick In Crude Inventories Is Leading To A Breakdown In Nabors Stock (NBR) The $4.5B oil driller earned more than $1 in EPS last year and is now projected to lose $0.22 and $0.12 this year and in 2016, respectively. The collapse in oil and gas prices is expected to cut sales in half from 2014 to 2016 ($3.4B-$3.5B). These projections may actually be too optimistic if this week’s U.S. crude oil inventory number is any indication.
Should You Buy Apogee Enterprises' 10% Correction, Or Are Its Best Days Behind It?
Odds are neither you nor anyone you know has heard of Apogee Enterprises APOG, but the products and design of the $1.5B glass solutions company have likely caught your eye before.
5 Stocks With Unusual Options Activity (CHK, AMD, HCA, NCR, PVA)
Here’s a quick look at 5 stocks showing unusual options activity with some color around the trading setups and recent news about the companies. Advanced Micro Devices (AMD) – Roughly 14,000 Aug $2.50 calls were purchased for $0.30. AMD is rumored to be looking at separating/ spinning off part of the business, but they have so far denied the Reuters report. AMD Micro Devices is scheduled to report Q2 earnings on July 16th.
Is It A Time To Buy Or Should You Still Avoid Actuant After The 40%+ Drop?
Back in July of 2000, Applied Power decided to spinoff the 100+ year old company's electronic business and renamed the Wisconsin-based industrial "Actuant (ATU)". Throughout their rich history they became a $1B company, acquiring and divesting dozens of businesses in various industries along the way.
HD Supply Is Benefiting From Solid U.S. Non-Residential Construction Demand
If your business, contractor, or municipality ever needed building supplies, backflow devices, or even just general maintenance services, there is a good chance you might have done business with HD Supply (HDS). Products sold range from fusible pipes and plumbing to forming lumber and copper wire. The $6.7B industrial distributor operates in the continental United States and several Canadian provinces serving more than a half-million customers through roughly 650 locations.
An Improving Jobs Market Is Leading Korn/Ferry Shares To 15-Year Highs
Los Angeles-based Korn/Ferry International (NYSE:KFY) is the largest talent management solutions provider in the world. The $1.7B company offers executive recruitment, leadership development programs, recruitment process outsourcing (they handle the interview, hiring, teaching, and speed at which a new hire is made for an employer), and succession planning.
Unusual Options Activity: GNC, TTWO, ATVI, and More
I’m back with my Sunday night review of several stocks that had unusual options activity during the prior week and what that may mean going forward. Although traders can never really be sure why these trades are taking place and who’s making them, I believe it’s important to be aware of notable options activity. Here’s my weekly recap 10 stocks that saw unusual options activity and what, if any, significance these trades may have.
Constellation Brands Shares Have Gotten Expensive Despite Growth From Corona
NEW YORK (TheStreet) -- Despite strong performance of late, Constellation Brands (STZ - Get Report ) is an expensive buy right now. Constellation is an $18 billion marketer and producer of more than 100 brands that include Corona Light, SVEDKA Vodka, Robert Mondavi Winery, and Red Velvet Whisky in roughly 100 countries.
Broadcom: Following A Stellar 2014 Performance, Does The Stock Have Any Room To Run?
NEW YORK ( TheStreet) – Broadcom (BRCM ) posted a stellar year, fueled by the semiconductor solution company's broadband and connectivity business. And while the Irvine, Calif., company hit a new 52-week high of $43.35 on Nov. 28 and its shares are up 47.5% year to date, a question investors are likely asking is whether the stock has more room to run. It does. And it's unlikely to end anytime soon. There are several different factors to take into account, when assessing Broadcom's future performance.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Mitchell
Contact Mitchell, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack